RecruitingACTRN12610000145000

Red Cell Life Span (RBC) in Chronic Kidney Disease (CKD)

Red Blood Cell (RBC) Survival in Patients with Chronic Kidney Disease (CKD) and on Dialysis


Sponsor

University of Otago

Enrollment

56 participants

Start Date

Oct 1, 2009

Study Type

Observational

Conditions

Summary

Anaemia associated with chronic kidney disease (CKD) is believed to be caused by erythropoietin deficiency and decreased red blood cell (RBC) survival. The toxic uremic environment and mechanical damage caused by dialysis is thought to account for the reduced red cell life span. However the clinical evidence for this is minimal. To date no accurate data on RBC survival in CKD is available. We propose to undertake a study to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium. As almost half the patients with CKD are diabetic, glycaemic control remains an important aspect of their management. Therefore RBC survival will influence the accuracy of markers of glycaemic control, like HbA1c.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is measuring how long red blood cells survive in people with chronic kidney disease (CKD). Red blood cells normally live about 120 days, but in people with kidney disease they may not last as long. Researchers will track this using a safe radioactive tag applied to the blood cells, and will also look at how this affects a common diabetes test called HbA1c. You may be eligible if: - You are 18 years of age or older - You have moderate CKD (stage III, with a filtration rate of 30–59 mL/min) OR you are on haemodialysis or peritoneal dialysis for at least 2 months OR you have diabetes with normal kidney function OR you are a healthy control You may NOT be eligible if: - You are on dialysis but not receiving erythropoietin (EPO) or iron treatment - Your haemoglobin (blood count) is outside the target range (110–130 g/L) - You have had recent blood loss or a blood transfusion - You have an active inflammatory illness - You have a solid organ cancer - You have unstable blood sugar control - You are pregnant Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study is designed to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by m

This study is designed to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium, whereby a sample of RBCs of a cross-section of ages is tagged and the disappearance of radioactivity is followed over a period of 4 weeks time.


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000145000


Related Trials